Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TH.TO
- Price
- 2.12
- Stock movement up
- +0.02 (0.95%)
- Company name
- Theratechnologies Inc.
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 97.48M
- Ent value
- 152.18M
- Price/Sales
- 1.16
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 10.24
- PEG
- -
- EPS growth
- 17.20%
- 1 year return
- -1.85%
- 3 year return
- -44.14%
- 5 year return
- -26.44%
- 10 year return
- -3.54%
Last updated: 2025-04-04
DIVIDENDS
TH.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 8.73 |
| EV to EBITDA | 13.62 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.16 |
| Price to Book | - |
| EV to Sales | 1.80 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 45.98M |
| EPS (TTM) | -0.06 |
| FCF per share (TTM) | -0.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 84.32M |
| Gross profit (TTM) | 64.90M |
| Operating income (TTM) | 9.93M |
| Net income (TTM) | -3.16M |
| EPS (TTM) | -0.06 |
| EPS (1y forward) | 0.21 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 76.97% |
| Operating margin (TTM) | 11.77% |
| Profit margin (TTM) | -3.75% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 34.69M |
| Net receivables | 10.31M |
| Total current assets | 57.25M |
| Goodwill | 0.00 |
| Intangible assets | 11.42M |
| Property, plant and equipment | 788.00K |
| Total assets | 69.71M |
| Accounts payable | 23.76M |
| Short/Current long term debt | 57.83M |
| Total current liabilities | 52.90M |
| Total liabilities | 89.39M |
| Shareholder's equity | -19.68M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -1.50M |
| Capital expenditures (TTM) | 3.00M |
| Free cash flow (TTM) | -4.50M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -4.53% |
| Return on Invested Capital | -8.33% |
| Cash Return on Invested Capital | -11.87% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.07 |
| Daily high | 2.17 |
| Daily low | 2.04 |
| Daily Volume | 23K |
| All-time high | 61.00 |
| 1y analyst estimate | 8.00 |
| Beta | 1.73 |
| EPS (TTM) | -0.06 |
| Dividend per share | - |
| Ex-div date | 10 Oct 2000 |
| Next earnings date | 8 Apr 2025 |
Downside potential
Loading...
Downside potential data
| TH.TO | S&P500 | |
| Current price drop from All-time high | -96.52% | -7.90% |
| Highest price drop | -98.69% | -56.47% |
| Date of highest drop | 1 Oct 2013 | 9 Mar 2009 |
| Avg drop from high | -66.22% | -11.07% |
| Avg time to new high | 199 days | 12 days |
| Max time to new high | 6142 days | 1805 days |
COMPANY DETAILS
Marketcap
97.48M
Marketcap category
Small-cap
Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Employees
103
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the C...
April 3, 2025
New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-s...
March 25, 2025
Theratechnologies (TH.TO) on Wednesday presented data demonstrating ibalizumab's (sold under the bra
March 12, 2025
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV Ibalizumab continues to demonstrate long-ter...
March 12, 2025
Study Demonstrates Excess Visceral Abdominal Fat Drives CV RiskMONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a co...
March 12, 2025
Theratechnologies Inc (THTX) reports a significant EBITDA improvement and outlines strategic plans for future growth amidst competitive challenges.
February 27, 2025
MONTREAL (AP) — Theratechnologies Inc. THTX) on Wednesday reported a loss of $7.9 million in its fiscal fourth quarter. On a per-share basis, the Montreal-based company said it had a loss of 16 cents.
February 26, 2025
Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of $25 million and annual ...
February 26, 2025
MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercializati...
February 14, 2025
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercializati...
February 14, 2025
Next page